Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | ACAD |
---|---|---|
09:32 ET | 2800 | 16.3 |
09:34 ET | 15280 | 16.15 |
09:36 ET | 100 | 16.19 |
09:38 ET | 100 | 16.19 |
09:39 ET | 400 | 16.17 |
09:41 ET | 1900 | 16.1999 |
09:43 ET | 750 | 16.13 |
09:45 ET | 3800 | 16.08 |
09:48 ET | 200 | 16.08 |
09:50 ET | 805 | 16.11 |
09:52 ET | 2155 | 16.19 |
09:54 ET | 1521 | 16.26 |
09:56 ET | 822 | 16.255 |
09:57 ET | 300 | 16.25 |
09:59 ET | 1400 | 16.255 |
10:01 ET | 2100 | 16.21 |
10:03 ET | 1203 | 16.19 |
10:06 ET | 2576 | 16.195 |
10:08 ET | 1176 | 16.18 |
10:10 ET | 1100 | 16.19 |
10:12 ET | 500 | 16.2 |
10:14 ET | 1100 | 16.2 |
10:15 ET | 1243 | 16.15 |
10:17 ET | 1338 | 16.19 |
10:19 ET | 1800 | 16.17 |
10:21 ET | 600 | 16.21 |
10:24 ET | 1600 | 16.235 |
10:26 ET | 1137 | 16.28 |
10:28 ET | 1781 | 16.29 |
10:30 ET | 3422 | 16.34 |
10:32 ET | 3225 | 16.34 |
10:33 ET | 1874 | 16.33 |
10:35 ET | 300 | 16.335 |
10:37 ET | 1643 | 16.35 |
10:39 ET | 3000 | 16.37 |
10:42 ET | 5490 | 16.37 |
10:44 ET | 300 | 16.375 |
10:46 ET | 1034 | 16.38 |
10:48 ET | 1283 | 16.4111 |
10:50 ET | 1732 | 16.41 |
10:51 ET | 943 | 16.42 |
10:53 ET | 2417 | 16.44 |
10:55 ET | 800 | 16.435 |
10:57 ET | 5089 | 16.45 |
11:00 ET | 3400 | 16.44 |
11:02 ET | 2966 | 16.42 |
11:04 ET | 881 | 16.405 |
11:06 ET | 2405 | 16.4 |
11:08 ET | 1706 | 16.405 |
11:09 ET | 600 | 16.4 |
11:11 ET | 1324 | 16.39 |
11:13 ET | 100 | 16.385 |
11:15 ET | 1400 | 16.4 |
11:18 ET | 2222 | 16.37 |
11:20 ET | 400 | 16.37 |
11:22 ET | 2401 | 16.3806 |
11:24 ET | 3098 | 16.38 |
11:26 ET | 886 | 16.36 |
11:27 ET | 700 | 16.36 |
11:29 ET | 1500 | 16.395 |
11:31 ET | 700 | 16.38 |
11:33 ET | 300 | 16.37 |
11:36 ET | 1621 | 16.35 |
11:38 ET | 1300 | 16.38 |
11:40 ET | 300 | 16.38 |
11:42 ET | 1900 | 16.36 |
11:44 ET | 1389 | 16.34 |
11:45 ET | 200 | 16.355 |
11:47 ET | 1100 | 16.35 |
11:49 ET | 400 | 16.355 |
11:51 ET | 1599 | 16.34 |
11:54 ET | 500 | 16.35 |
11:56 ET | 2372 | 16.37 |
11:58 ET | 100 | 16.375 |
12:00 ET | 1100 | 16.365 |
12:02 ET | 400 | 16.36 |
12:03 ET | 600 | 16.36 |
12:05 ET | 2455 | 16.34 |
12:07 ET | 600 | 16.355 |
12:09 ET | 3908 | 16.385 |
12:12 ET | 500 | 16.39 |
12:14 ET | 2148 | 16.38 |
12:16 ET | 200 | 16.39 |
12:18 ET | 1591 | 16.38 |
12:20 ET | 1100 | 16.37 |
12:21 ET | 300 | 16.375 |
12:23 ET | 600 | 16.38 |
12:25 ET | 1997 | 16.39 |
12:27 ET | 800 | 16.4 |
12:30 ET | 500 | 16.405 |
12:32 ET | 500 | 16.405 |
12:34 ET | 1220 | 16.4 |
12:36 ET | 500 | 16.41 |
12:38 ET | 2631 | 16.405 |
12:39 ET | 200 | 16.41 |
12:41 ET | 1937 | 16.39 |
12:43 ET | 1176 | 16.37 |
12:45 ET | 500 | 16.365 |
12:50 ET | 1572 | 16.36 |
12:52 ET | 393 | 16.355 |
12:54 ET | 800 | 16.345 |
12:56 ET | 1043 | 16.35 |
12:57 ET | 1042 | 16.36 |
12:59 ET | 1600 | 16.355 |
01:01 ET | 1135 | 16.361 |
01:03 ET | 1232 | 16.36 |
01:06 ET | 1200 | 16.36 |
01:08 ET | 830 | 16.36 |
01:12 ET | 400 | 16.365 |
01:14 ET | 1614 | 16.36 |
01:15 ET | 451 | 16.36 |
01:17 ET | 100 | 16.36 |
01:19 ET | 300 | 16.37 |
01:21 ET | 500 | 16.375 |
01:24 ET | 100 | 16.38 |
01:26 ET | 2036 | 16.375 |
01:28 ET | 700 | 16.385 |
01:30 ET | 1400 | 16.39 |
01:32 ET | 500 | 16.39 |
01:33 ET | 1925 | 16.4 |
01:35 ET | 300 | 16.4 |
01:37 ET | 590 | 16.4 |
01:39 ET | 1000 | 16.385 |
01:42 ET | 950 | 16.42 |
01:44 ET | 1281 | 16.42 |
01:46 ET | 1100 | 16.425 |
01:48 ET | 2000 | 16.415 |
01:50 ET | 800 | 16.41 |
01:51 ET | 1305 | 16.395 |
01:53 ET | 1500 | 16.405 |
01:55 ET | 1875 | 16.4 |
01:57 ET | 200 | 16.395 |
02:00 ET | 3811 | 16.4 |
02:02 ET | 20908 | 16.6 |
02:04 ET | 8506 | 16.66 |
02:06 ET | 1900 | 16.61 |
02:08 ET | 3501 | 16.59 |
02:09 ET | 1200 | 16.49 |
02:11 ET | 700 | 16.495 |
02:13 ET | 7050 | 16.38 |
02:15 ET | 4255 | 16.42 |
02:18 ET | 12469 | 16.48 |
02:20 ET | 2790 | 16.53 |
02:22 ET | 3120 | 16.55 |
02:24 ET | 800 | 16.53 |
02:26 ET | 1586 | 16.55 |
02:27 ET | 1032 | 16.57 |
02:29 ET | 19344 | 16.63 |
02:31 ET | 7068 | 16.65 |
02:33 ET | 2276 | 16.65 |
02:36 ET | 12162 | 16.66 |
02:38 ET | 6452 | 16.62 |
02:40 ET | 6608 | 16.725 |
02:42 ET | 1599 | 16.69 |
02:44 ET | 4365 | 16.6 |
02:45 ET | 7421 | 16.45 |
02:47 ET | 11909 | 16.58 |
02:49 ET | 5605 | 16.57 |
02:51 ET | 2607 | 16.57 |
02:54 ET | 1997 | 16.67 |
02:56 ET | 600 | 16.65 |
02:58 ET | 1678 | 16.669 |
03:00 ET | 2100 | 16.55 |
03:02 ET | 5825 | 16.54 |
03:03 ET | 7648 | 16.54 |
03:05 ET | 3700 | 16.52 |
03:07 ET | 4287 | 16.42 |
03:09 ET | 1398 | 16.42 |
03:12 ET | 2231 | 16.475 |
03:14 ET | 7449 | 16.525 |
03:16 ET | 1100 | 16.54 |
03:18 ET | 1481 | 16.51 |
03:20 ET | 4695 | 16.5 |
03:21 ET | 3095 | 16.44 |
03:23 ET | 3700 | 16.4 |
03:25 ET | 1100 | 16.41 |
03:27 ET | 3200 | 16.441 |
03:30 ET | 2900 | 16.49 |
03:32 ET | 2627 | 16.47 |
03:34 ET | 2914 | 16.45 |
03:36 ET | 1950 | 16.41 |
03:38 ET | 3349 | 16.39 |
03:39 ET | 2271 | 16.415 |
03:41 ET | 3000 | 16.4 |
03:43 ET | 1400 | 16.41 |
03:45 ET | 5947 | 16.37 |
03:48 ET | 2889 | 16.35 |
03:50 ET | 2811 | 16.33 |
03:52 ET | 3246 | 16.355 |
03:54 ET | 3188 | 16.38 |
03:56 ET | 7941 | 16.37 |
03:57 ET | 5644 | 16.355 |
03:59 ET | 157788 | 16.33 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
ACADIA Pharmaceuticals Inc | 2.7B | 90.1x | --- |
Azenta Inc | 2.4B | -17.5x | --- |
PTC Therapeutics Inc | 2.7B | -5.6x | --- |
Guardant Health Inc | 3.1B | -6.1x | --- |
Novavax Inc | 2.1B | -4.5x | --- |
Catalyst Pharmaceuticals Inc | 2.4B | 38.3x | --- |
Acadia Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has a portfolio of commercial stage products, in-development product opportunities, and research programs that are designed to address unmet needs in CNS disorders and rare diseases. Its pipeline includes NUPLAZID (pimavanserin), DAYBUE (trofinetide), ACP-101, ACP-204, and Antisense Oligonucleotide (ASO) Programs. NUPLAZID is a selective serotonin inverse agonist/antagonist preferentially targeting the 5-HT2A receptor. NUPLAZID is developed for the treatment for Parkinson's Disease Psychosis. Trofinetide is a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 (IGF-1) designed to treat the core symptoms of Rett syndrome by reducing neuroinflammation and supporting synaptic function.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $2.7B |
---|---|
Revenue (TTM) | $890.5M |
Shares Outstanding | 165.9M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.39 |
EPS | $0.18 |
Book Value | $2.62 |
P/E Ratio | 90.1x |
Price/Sales (TTM) | 3.0 |
Price/Cash Flow (TTM) | 64.2x |
Operating Margin | 2.56% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.